Skip to main content

SpringWorks Therapeutics, Inc.

SWTXDelisted
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001773427

SpringWorks Therapeutics, Inc. was delisted in 2025; its insiders filed their last Form 4 on Jul 2, 2025; 223 institutions reported holding it in 13F filings for Q2 2025, worth $3.68B in total; Soros Fund Management was the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by SpringWorks Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for SpringWorks Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for SpringWorks Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Lynch DanielDirector0Jul 2, 20250
Fuhrman AlanDirector0Jul 2, 20250
Perier Francis I JrChief Financial Officer0Jul 2, 20250
Weinstein Herschel SGeneral Counsel & Secretary0Jul 2, 20250
Mackay MartinDirector0Jul 2, 20250
Lewis-Hall Freda CDirector0Jul 2, 20250
Alban CarlosDirector0Jul 2, 20250
Islam SaqibChief Executive Officer0Jul 2, 20250
Hambleton JulieDirector0Jul 2, 20250
Nofi MichaelChief Accounting Officer0Jul 2, 20250
Edris BadreddinChief Operating Officer0Jul 2, 20250
Pichl DanielChief People Officer0Jul 2, 20250
Ashar BhaveshChief Commercial Officer0Jul 2, 20250
Cassidy JamesChief Medical Officer0Jul 2, 20250
Lin Tai-AnChief Scientific Officer0Jul 2, 20250
Smith L. MaryChief Development Officer233,363Jan 8, 20240
Schwartz Jeffrey LawrenceDirector10,572May 25, 20230
OrbiMed Advisors LLC10% Owner5,599,842IndirectSep 14, 20220
OrbiMed Capital GP VI LLC10% Owner5,599,842IndirectSep 14, 20220
Burgess Michael F.Head of Research & Development49,584Jul 20, 20220
Squinto Stephen PDirector, 10% Owner131,652May 20, 20220
Koppel Adam10% Owner4,831,307IndirectAug 12, 20210
Bain Capital Life Sciences Investors, LLC10% Owner4,831,307IndirectAug 12, 20210
BC SW, LP10% Owner4,831,307IndirectAug 12, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Mar 5, 2025 (view filing)Mar 32 daysEdris BadreddinChief Operating OfficerSSale−20.0K$54.23−$1.08M−10.5%169.7K after4 lots10b5-1
Mar 5, 2025 (view filing)Mar 32 daysIslam SaqibChief Executive OfficerSSale−49.0K$54.24−$2.66M−4.9%954.9K after5 lots10b5-1
Feb 24, 2025 (view filing)Feb 204 daysIslam SaqibChief Executive OfficerSSale−29.3K$60.30−$1.77M−2.8%1.03M after2 lots10b5-1
Feb 24, 2025 (view filing)Feb 204 daysAshar BhaveshChief Commercial OfficerSSale−1.02K$61.19−$62.2K−1.6%62.1K after10b5-1
Feb 24, 2025 (view filing)Feb 204 daysLynch DanielDirectorSSale−47.6K$60.22−$2.87M−36.5%82.9K after2 lots10b5-1
Feb 19, 2025 (view filing)Feb 145 daysIslam SaqibChief Executive OfficerSSale−10.7K$59.92−$639.5K−1.0%1.06M after10b5-1
Feb 19, 2025 (view filing)Feb 145 daysLynch DanielDirectorSSale−400$60.00−$24.0K−0.3%130.5K after10b5-1
Feb 12, 2025 (view filing)Feb 102 daysPichl DanielChief People OfficerSSale−29.8K$54.36−$1.62M−37.0%50.8K after3 lots10b5-1
Feb 12, 2025 (view filing)Feb 102 daysLynch DanielDirectorSSale−175.0K$54.46−$9.53M−57.2%130.9K after3 lots10b5-1
Feb 12, 2025 (view filing)Feb 102 daysIslam SaqibChief Executive OfficerSSale−48.0K$53.30−$2.56M−4.6%1.00M after10b5-1
Feb 12, 2025 (view filing)Feb 102 daysHambleton JulieDirectorSSale−13.8K$53.01−$730.2K−77.1%4.09K after10b5-1
Feb 12, 2025 (view filing)Feb 102 daysEdris BadreddinChief Operating OfficerSSale−30.0K$53.13−$1.59M−13.7%189.7K after10b5-1
Dec 5, 2024 (view filing)Dec 32 daysEdris BadreddinChief Operating OfficerSSale−20.0K$41.96−$839.3K−8.7%209.6K after2 lots10b5-1
Dec 4, 2024 (view filing)Dec 22 daysIslam SaqibChief Executive OfficerSSale−49.0K$41.37−$2.03M−4.6%1.01M after2 lots10b5-1
Sep 4, 2024 (view filing)Sep 31 dayIslam SaqibChief Executive OfficerSSale−49.0K$40.57−$1.99M−4.4%1.06M after3 lots10b5-1
Sep 4, 2024 (view filing)Sep 31 dayEdris BadreddinChief Operating OfficerSSale−20.0K$40.65−$812.9K−8.0%229.6K after3 lots10b5-1
Jun 5, 2024 (view filing)Jun 32 daysIslam SaqibChief Executive OfficerSSale−49.0K$39.90−$1.96M−4.2%1.11M after4 lots10b5-1
Jun 5, 2024 (view filing)Jun 32 daysHambleton JulieDirectorSSale−4.65K$40.03−$186.0K−53.2%4.09K after4 lots10b5-1
Jun 5, 2024 (view filing)Jun 32 daysEdris BadreddinChief Operating OfficerSSale−20.0K$40.07−$801.4K−7.4%249.6K after4 lots10b5-1
Feb 20, 2024 (view filing)Feb 164 daysPichl DanielChief People OfficerSSale−15.0K$50.10−$751.5K−24.9%45.2K after10b5-1
Feb 5, 2024 (view filing)Feb 2-53 daysAshar BhaveshChief Commercial OfficerSSale−8.06K$47.34−$381.4K−12.2%58.2K after5 lots
Feb 5, 2024 (view filing)Feb 23 daysPichl DanielChief People OfficerSSale−26.2K$44.32−$1.16M−36.7%45.2K after4 lots10b5-1
Jul 21, 2023 (view filing)Jul 192 daysHambleton JulieDirectorSSale−2.42K$29.31−$70.9K−34.2%4.65K after10b5-1
Jun 22, 2023 (view filing)Jun 202 daysHambleton JulieDirectorSSale−2.40K$26.92−$64.6K−25.4%7.07K after10b5-1
Mar 20, 2023 (view filing)Mar 164 daysSchwartz Jeffrey LawrenceDirectorSSale−1.75M$28.50−$49.9M−36.2%3.08M after
Mar 16, 2023 (view filing)Mar 151 dayHambleton JulieDirectorSSale−1.11K$31.50−$34.8K−18.7%4.82K after
Jan 27, 2023 (view filing)Jan 261 dayPichl DanielChief People OfficerSSale−858$31.00−$26.6K−2.4%35.2K after
Sep 14, 2022 (view filing)4:24 PM ETSep 122 daysOrbiMed Advisors LLC and 1 other10% OwnerSSale−153.9K$31.96−$4.92M−2.7%5.60M after2 lots
Aug 10, 2022 (view filing)4:22 PM ETAug 8-92 daysOrbiMed Advisors LLC and 1 other10% OwnerSSale−274.6K$38.11−$10.5M−4.6%5.75M after2 lots
Oct 20, 2021 (view filing)Oct 20Same dayIslam SaqibChief Executive OfficerSSale−10.1K$58.67−$591.6K−1.3%779.2K after
Oct 19, 2021 (view filing)Oct 18-191 dayIslam SaqibChief Executive OfficerSSale−52.4K$58.65−$3.07M−6.4%769.1K after2 lots
Oct 13, 2021 (view filing)Oct 13Same daySmith L. MaryChief Development OfficerSSale−10.0K$55.97−$559.7K−5.6%167.5K after
Aug 12, 2021 (view filing)8:38 PM ETAug 102 daysSchwartz Jeffrey Lawrence and 3 othersDirector, 10% OwnerSSale−1.00M$70.25−$70.3M−17.1%4.83M after
Jul 20, 2021 (view filing)Jul 19-201 dayIslam SaqibChief Executive OfficerSSale−62.5K$76.56−$4.79M−7.1%821.6K after2 lots
Jul 14, 2021 (view filing)Jul 131 daySmith L. MaryChief Development OfficerSSale−10.0K$80.88−$808.8K−5.6%167.5K after
Jul 6, 2021 (view filing)4:42 PM ETJul 15 daysOrbiMed Advisors LLC and 1 other10% OwnerSSale−16.0K$85.01−$1.36M−0.3%6.03M after
Jul 1, 2021 (view filing)Jul 1Same dayEdris BadreddinChief Operating OfficerSSale−32.0K$85.35−$2.73M−9.6%301.5K after